WEKO3
アイテム
{"_buckets": {"deposit": "dbab1d08-ad71-48ac-84be-3cd66c042f34"}, "_deposit": {"created_by": 31, "id": "2399", "owners": [31], "pid": {"revision_id": 0, "type": "depid", "value": "2399"}, "status": "published"}, "_oai": {"id": "oai:oist.repo.nii.ac.jp:00002399", "sets": ["213"]}, "author_link": ["15921", "15914", "15916", "15917", "15919", "15913", "15915", "15920", "15918"], "item_10001_biblio_info_7": {"attribute_name": "Bibliographic Information", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2021-11-24", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "12", "bibliographicPageStart": "3291", "bibliographicVolumeNumber": "10", "bibliographic_titles": [{}, {"bibliographic_title": "Cells", "bibliographic_titleLang": "en"}]}]}, "item_10001_creator_3": {"attribute_name": "Author", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Dewanjee, Saikat"}], "nameIdentifiers": [{"nameIdentifier": "15913", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kandimalla, Ramesh"}], "nameIdentifiers": [{"nameIdentifier": "15914", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kalra, Rajkumar Singh"}], "nameIdentifiers": [{"nameIdentifier": "15915", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Valupadas, Chandrasekhar"}], "nameIdentifiers": [{"nameIdentifier": "15916", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Vallamkondu, Jayalakshmi"}], "nameIdentifiers": [{"nameIdentifier": "15917", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kolli, Viswakalyan"}], "nameIdentifiers": [{"nameIdentifier": "15918", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Dey Ray, Sarbani"}], "nameIdentifiers": [{"nameIdentifier": "15919", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Reddy, Arubala P."}], "nameIdentifiers": [{"nameIdentifier": "15920", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Reddy, P. Hemachandra"}], "nameIdentifiers": [{"nameIdentifier": "15921", "nameIdentifierScheme": "WEKO"}]}]}, "item_10001_description_5": {"attribute_name": "Abstract", "attribute_value_mlt": [{"subitem_description": "Hyperactivation of immune responses resulting in excessive release of pro-inflammatory mediators in alveoli/lung structures is the principal pathological feature of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The cytokine hyperactivation in COVID-19 appears to be similar to those seen in rheumatoid arthritis (RA), an autoimmune disease. Emerging evidence conferred the severity and risk of COVID-19 to RA patients. Amid the evidence of musculoskeletal manifestations involving immune-inflammation-dependent mechanisms and cases of arthralgia and/or myalgia in COVID-19, crosstalk between COVID-19 and RA is often debated. The present article sheds light on the pathological crosstalk between COVID-19 and RA, the risk of RA patients in acquiring SARS-CoV-2 infection, and the aspects of SARS-CoV-2 infection in RA development. We also conferred whether RA can exacerbate COVID-19 outcomes based on available clinical readouts. The mechanistic overlapping in immune-inflammatory features in both COVID-19 and RA was discussed. We showed the emerging links of angiotensin-converting enzyme (ACE)-dependent and macrophage-mediated pathways in both diseases. Moreover, a detailed review of immediate challenges and key recommendations for anti-rheumatic drugs in the COVID-19 setting was presented for better clinical monitoring and management of RA patients. Taken together, the present article summarizes available knowledge on the emerging COVID-19 and RA crosstalk and their mechanistic overlaps, challenges, and therapeutic options.", "subitem_description_type": "Other"}]}, "item_10001_publisher_8": {"attribute_name": "Publisher", "attribute_value_mlt": [{"subitem_publisher": "MDPI"}]}, "item_10001_relation_14": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "info:doi/10.3390/cells10123291", "subitem_relation_type_select": "DOI"}}]}, "item_10001_relation_17": {"attribute_name": "Related site", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "https://www.mdpi.com/2073-4409/10/12/3291/htm", "subitem_relation_type_select": "URI"}}]}, "item_10001_rights_15": {"attribute_name": "Rights", "attribute_value_mlt": [{"subitem_rights": "© 2021 The Author(s)"}]}, "item_10001_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "2073-4409", "subitem_source_identifier_type": "ISSN"}]}, "item_10001_version_type_20": {"attribute_name": "Author\u0027s flag", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2021-12-01"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "cells-10-03291_a.pdf", "filesize": [{"value": "2.8 MB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensefree": "CC BY 4.0\nCreative Commons Attribution 4.0 International (https://creativecommons.org/licenses/by/4.0/)", "licensetype": "license_free", "mimetype": "application/pdf", "size": 2800000.0, "url": {"label": "cells-10-03291_a", "url": "https://oist.repo.nii.ac.jp/record/2399/files/cells-10-03291_a.pdf"}, "version_id": "4e789254-4ad3-4823-a51c-cbab6e4373fd"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "ACE", "subitem_subject_scheme": "Other"}, {"subitem_subject": "ACE2", "subitem_subject_scheme": "Other"}, {"subitem_subject": "anti-rheumatic drugs", "subitem_subject_scheme": "Other"}, {"subitem_subject": "COVID-19", "subitem_subject_scheme": "Other"}, {"subitem_subject": "cytokine storm", "subitem_subject_scheme": "Other"}, {"subitem_subject": "immune response", "subitem_subject_scheme": "Other"}, {"subitem_subject": "inflammation", "subitem_subject_scheme": "Other"}, {"subitem_subject": "rheumatoid arthritis", "subitem_subject_scheme": "Other"}, {"subitem_subject": "SARS-CoV-2", "subitem_subject_scheme": "Other"}, {"subitem_subject": "therapeutic options", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "COVID-19 and Rheumatoid Arthritis Crosstalk: Emerging Association, Therapeutic Options and Challenges", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "COVID-19 and Rheumatoid Arthritis Crosstalk: Emerging Association, Therapeutic Options and Challenges", "subitem_title_language": "en"}]}, "item_type_id": "10001", "owner": "31", "path": ["213"], "permalink_uri": "https://oist.repo.nii.ac.jp/records/2399", "pubdate": {"attribute_name": "公開日", "attribute_value": "2021-12-01"}, "publish_date": "2021-12-01", "publish_status": "0", "recid": "2399", "relation": {}, "relation_version_is_last": true, "title": ["COVID-19 and Rheumatoid Arthritis Crosstalk: Emerging Association, Therapeutic Options and Challenges"], "weko_shared_id": 31}
COVID-19 and Rheumatoid Arthritis Crosstalk: Emerging Association, Therapeutic Options and Challenges
https://oist.repo.nii.ac.jp/records/2399
https://oist.repo.nii.ac.jp/records/239951656a8b-49b2-4fee-9121-d919aa72cc41
名前 / ファイル | ライセンス | アクション |
---|---|---|
cells-10-03291_a (2.8 MB)
|
CC BY 4.0
Creative Commons Attribution 4.0 International (https://creativecommons.org/licenses/by/4.0/) |
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2021-12-01 | |||||
タイトル | ||||||
言語 | en | |||||
タイトル | COVID-19 and Rheumatoid Arthritis Crosstalk: Emerging Association, Therapeutic Options and Challenges | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | ACE | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | ACE2 | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | anti-rheumatic drugs | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | COVID-19 | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | cytokine storm | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | immune response | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | inflammation | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | rheumatoid arthritis | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | SARS-CoV-2 | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | therapeutic options | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者(英) |
Dewanjee, Saikat
× Dewanjee, Saikat× Kandimalla, Ramesh× Kalra, Rajkumar Singh× Valupadas, Chandrasekhar× Vallamkondu, Jayalakshmi× Kolli, Viswakalyan× Dey Ray, Sarbani× Reddy, Arubala P.× Reddy, P. Hemachandra |
|||||
書誌情報 |
en : Cells 巻 10, 号 12, p. 3291, 発行日 2021-11-24 |
|||||
抄録 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Hyperactivation of immune responses resulting in excessive release of pro-inflammatory mediators in alveoli/lung structures is the principal pathological feature of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The cytokine hyperactivation in COVID-19 appears to be similar to those seen in rheumatoid arthritis (RA), an autoimmune disease. Emerging evidence conferred the severity and risk of COVID-19 to RA patients. Amid the evidence of musculoskeletal manifestations involving immune-inflammation-dependent mechanisms and cases of arthralgia and/or myalgia in COVID-19, crosstalk between COVID-19 and RA is often debated. The present article sheds light on the pathological crosstalk between COVID-19 and RA, the risk of RA patients in acquiring SARS-CoV-2 infection, and the aspects of SARS-CoV-2 infection in RA development. We also conferred whether RA can exacerbate COVID-19 outcomes based on available clinical readouts. The mechanistic overlapping in immune-inflammatory features in both COVID-19 and RA was discussed. We showed the emerging links of angiotensin-converting enzyme (ACE)-dependent and macrophage-mediated pathways in both diseases. Moreover, a detailed review of immediate challenges and key recommendations for anti-rheumatic drugs in the COVID-19 setting was presented for better clinical monitoring and management of RA patients. Taken together, the present article summarizes available knowledge on the emerging COVID-19 and RA crosstalk and their mechanistic overlaps, challenges, and therapeutic options. | |||||
出版者 | ||||||
出版者 | MDPI | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 2073-4409 | |||||
DOI | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | DOI | |||||
関連識別子 | info:doi/10.3390/cells10123291 | |||||
権利 | ||||||
権利情報 | © 2021 The Author(s) | |||||
関連サイト | ||||||
識別子タイプ | URI | |||||
関連識別子 | https://www.mdpi.com/2073-4409/10/12/3291/htm | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 |